In summary, our study demonstrates that linagliptin monotherapy exerts a certain degree of renoprotection in the treatment of lupus nephritis, but it also reveals that this treatment is accompanied by an upregulation of the CXCL12/CXCR4 signaling axis, which may potentially compromise renal protection. Here, CXCR4 is linked to lupus nephritis.